Federal Register / Vol. 88, No. 190 / Tuesday, October 3, 2023 / Notices 68147 

1Established Aggregate Production Quotas for 

Schedule I and II Controlled Substances and 

Assessment of Annual Needs for the List I 

Chemicals Ephedrine, Pseudoephedrine, and 

Phenylpropanolamine for 2023, 87 FR 74168 

(December 2, 2022). 

Total Estimated Number of Annual 

Burden Hours: 758. 

Respondent’s Obligation: Required to 

obtain or retain a benefit. 

Frequency of Collection: On occasion. 

Total Estimated Annual Nonhour 

Burden Cost: None. 

An agency may not conduct or 

sponsor and a person is not required to 

respond to a collection of information 

unless it displays a currently valid OMB 

control number. 

The authority for this action is the 

Paperwork Reduction Act of 1995 (44 

U.S.C. 3501 et seq.). 

Phadrea Ponds, 

Information Collection Clearance Officer, 

National Park Service. 

[FR Doc. 2023–21778 Filed 10–2–23; 8:45 am] 

BILLING CODE 4312–52–P 

JUDICIAL CONFERENCE OF THE 

UNITED STATES 

Advisory Committee on Appellate 

Rules; Hearing of the Judicial 

Conference 

AGENCY: Judicial Conference of the 

United States. 

ACTION: Advisory Committee on 

Appellate Rules; notice of cancellation 

of open hearing. 

SUMMARY: The following public hearing 

on proposed amendments to the Federal 

Rules of Appellate Procedure has been 

canceled: Appellate Rules Hearing on 

October 18, 2023. The announcement 

for this hearing was previously 

published in the Federal Register on 

August 9, 2023. 

DATES: October 18, 2023. 

FOR FURTHER INFORMATION CONTACT: H. 

Thomas Byron III, Esq., Chief Counsel, 

Rules Committee Staff, Administrative 

Office of the U.S. Courts, Thurgood 

Marshall Federal Judiciary Building, 

One Columbus Circle NE, Suite 7–300, 

Washington, DC 20544, Phone (202) 

502–1820, RulesCommittee_Secretary@

ao.uscourts.gov. 

(Authority: 28 U.S.C. 2073.) 

Dated: September 26, 2023. 

Shelly L. Cox, 

Management Analyst, Rules Committee Staff. 

[FR Doc. 2023–21829 Filed 10–2–23; 8:45 am] 

BILLING CODE 2210–55–P 

JUDICIAL CONFERENCE OF THE 

UNITED STATES 

Committee on Rules of Practice and 

Procedure; Meeting of the Judicial 

Conference 

AGENCY: Judicial Conference of the 

United States. 

ACTION: Committee on Rules of Practice 

and Procedure; notice of open meeting. 

SUMMARY: The Committee on Rules of 

Practice and Procedure will hold a 

meeting in a hybrid format with remote 

attendance options on January 4, 2024 

in Austin, TX. The meeting is open to 

the public for observation but not 

participation. An agenda and supporting 

materials will be posted at least 7 days 

in advance of the meeting at: https://

www.uscourts.gov/rules-policies/ 

records-and-archives-rules-committees/ 

agenda-books. 

DATES: January 4, 2024. 

FOR FURTHER INFORMATION CONTACT: H. 

Thomas Byron III, Esq., Chief Counsel, 

Rules Committee Staff, Administrative 

Office of the U.S. Courts, Thurgood 

Marshall Federal Judiciary Building, 

One Columbus Circle NE, Suite 7–300, 

Washington, DC 20544, Phone (202) 

502–1820, RulesCommittee_Secretary@

ao.uscourts.gov. 

(Authority: 28 U.S.C. 2073.) 

Dated: September 26, 2023. 

Shelly L. Cox, 

Management Analyst, Rules Committee Staff. 

[FR Doc. 2023–21830 Filed 10–2–23; 8:45 am] 

BILLING CODE 2210–55–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–1051M] 

Adjustment to the Aggregate 

Production Quota for Methylphenidate 

(for Sale) for 2023 

AGENCY: Drug Enforcement 

Administration, Department of Justice. 

ACTION: Final order. 

SUMMARY: The Drug Enforcement 

Administration is adjusting the 2023 

aggregate production quota for the 

schedule II controlled substance 

methylphenidate (for sale). 

DATES: This final order is effective 

October 3, 2023. 

FOR FURTHER INFORMATION CONTACT: 

Scott A. Brinks, Regulatory Drafting and 

Policy Support Section, Diversion 

Control Division, Drug Enforcement 

Administration, Telephone: (571) 776– 

3882. 

SUPPLEMENTARY INFORMATION: 

Legal Authority 

Section 306 of the Controlled 

Substances Act (CSA) (21 U.S.C. 826) 

requires the Attorney General to 

establish aggregate production quotas 

(APQ) for each basic class of controlled 

substance listed in schedule I and II. 

The Attorney General has delegated this 

function to the Administrator of the 

Drug Enforcement Administration 

(DEA) pursuant to 28 CFR 0.100. 

Under 21 U.S.C. 826(h), when a 

request for individual manufacturing 

quota is submitted by a DEA-registered 

manufacturer pertaining to a schedule II 

controlled substance that is contained in 

a drug on FDA’s list of drugs in 

shortage, DEA must complete review of 

such request not later than 30 days after 

receipt of the request. If, after the review 

is completed, DEA finds it necessary to 

address a shortage of that controlled 

substance, DEA is to increase the 

aggregate and individual production 

quotas of that controlled substance and 

any ingredient therein to the level 

requested. 21 U.S.C. 826(h)(1)(B)(i). 

However, if it is determined that the 

level requested is not necessary to 

address the shortage, DEA is to provide 

a written response detailing the basis for 

the determination. 21 U.S.C. 

826(h)(1)(B)(ii). 

Background 

DEA published the 2023 established 

APQ for controlled substances in 

schedules I and II in the Federal 

Register on December 2, 2022. 87 FR 

74168. The 2023 established APQ 

represents those quantities of schedule 

I and II controlled substances that may 

be manufactured in the United States to 

provide for the estimated medical, 

scientific, research, and industrial needs 

of the United States, for lawful export 

requirements, and for the establishment 

and maintenance of reserve stocks. 

These quotas do not include imports of 

controlled substances for use in 

industrial processes. The final order 

stipulated that all APQ are subject to an 

adjustment, in accordance with 21 CFR 

1303.15.1

Quotas Applicable to Drugs in Shortage 

Pursuant to 21 U.S.C. 826(h) 

DEA received written correspondence 

from FDA on August 10, 2023, in 

accordance with 21 U.S.C. 356c, 

addressing the domestic drug shortage 


ddrumheller on DSK120RN23PROD with NOTICES1